|Videos|July 1, 2017

Adopting a Suitable Stewardship Intervention for Your Practice Setting

Conan MacDougall, PharmD, explains how practitioners can adopt antibiotic stewardship interventions that will be beneficial to their specific practice settings.

Conan MacDougall, PharmD, professor of clinical pharmacy, University of California, San Francisco, explains how practitioners can adopt antibiotic stewardship interventions that will be beneficial to their specific practice settings.

Interview Transcript (slightly modified for readability)

“When you’re considering whether to adopt a particular intervention for your practice setting, it’s important to try and match your institutional strengths with the different strategies that you’re looking at. If your institution has a strong [information technology] IT department, that’s willing to work with you, that might be a good place to start because it scales easily. A lot of places have more challenges with their IT department, and so, that might not be something that [they] want to start with, in terms of forcing an issue that’s not really easily accessible for your hospital.

The other thing to think about is in a particular practice setting, trying to start a pilot program. So, finding a particular group of practitioners that are willing to be subjected to the intervention [and] provide some initial feedback. You can provide an assessment of how well it’s working, and lessons for improvement, before you scale it up to a larger group of practitioners.”


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.